FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322774908> ?p ?o ?g. }

• W4322774908 endingPage "07" @default.
• W4322774908 startingPage "P6" @default.
• W4322774908 abstract "Abstract Background: Historically, less than 10% of adult patients with cancer enroll in clinical trials, however, enrollment dropped further at the onset of the COVID-19 pandemic. Barriers to trial participation during the pandemic have not been reported. As part of the TBCRC 057 survey on the impact of the pandemic on willingness to participate in breast cancer trials, we assessed reasons for reluctance to participate in trials during the pandemic. Methods: US residents who self-reported a breast cancer diagnosis were eligible to complete the online survey 8/6/21-9/30/21. Respondents indicated whether they were current trial participants and, if not, their willingness to consider participating in a trial during the pandemic using a 5-point scale (0-not at all willing to 4-definitely willing). Respondents who were not current trial participants and who were not “definitely willing” to consider participation during the pandemic were characterized as “reluctant” and asked to select reasons for their reluctance from a checklist. Pandemic-related anxiety was assessed on an 11-point scale (0-no anxiety to 10-worst anxiety possible). Respondents indicated how the option to conduct trial activities online would affect their decision to participate in a trial (much less likely, somewhat less likely, would not affect my decision, somewhat more likely, or much more likely). In exploratory analyses, we evaluated whether pandemic-related anxiety and favorable reactions towards opportunities to conduct trial activities online were associated with reluctance to consider trial participation during the pandemic due to fear of SARS-CoV-2 exposure. Means were compared with two sample t-tests and proportions with Fisher’s exact tests. Results: Of 385 survey respondents, 185 (48%) were characterized as reluctant to consider trial participation during the pandemic. Among these 185, median age was 55 (range 25-80), 85.7% were non-Hispanic White, 48.1% had metastatic disease and 44.2% received care at academic centers. Reasons for reluctance to consider trial participation during the pandemic cited by ≥15% of the 185 reluctant respondents are shown in the Table. Respondents who selected fear of exposure to SARS-CoV-2 as a reason for their reluctance to consider participating in a trial during the pandemic had higher mean pandemic-related anxiety (7.0 vs 5.2, p&lt; 0.001). These respondents were more likely to indicate telemedicine doctor visits (p=0.01), virtual consents (p=0.001) and online study questionnaires (p=0.001) would make them somewhat or much more likely to participate in trials than respondents who did not select fear of exposure to SARS-CoV-2 as a reason for their reluctance. Conclusions: Reasons for reluctance of patients with breast cancer to consider participation in clinical trials during the pandemic are multifactorial. Although concerns about safety and efficacy remain prominent, fear of exposure to SARS-CoV-2 drives unwillingness to participate in &gt;25% of reluctant patients. Trial accrual may benefit from incorporation of electronic activities when possible. Table Citation Format: Karen L. Smith, Carolyn Mead-Harvey, Gina L. Mazza, Albert E. Holler, Eileen Shinn, Elizabeth Frank, Michelle Melisko, Cyd Eaton, Jeannine M. Salamone, Teri Pollastro, Patricia Spears, Antonio C. Wolff, Gabrielle B. Rocque. Reasons for Reduced Willingness to Participate in Clinical Trials During the COVID-19 Pandemic: The Translational Breast Cancer Research Consortium (TBCRC) 057 Survey [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-08-07." @default.
• W4322774908 created "2023-03-03" @default.
• W4322774908 creator A5000761973 @default.
• W4322774908 creator A5022943610 @default.
• W4322774908 creator A5026024346 @default.
• W4322774908 creator A5026681970 @default.
• W4322774908 creator A5029658073 @default.
• W4322774908 creator A5032886944 @default.
• W4322774908 creator A5035746810 @default.
• W4322774908 creator A5048410090 @default.
• W4322774908 creator A5049065026 @default.
• W4322774908 creator A5052259481 @default.
• W4322774908 creator A5062171182 @default.
• W4322774908 creator A5064707298 @default.
• W4322774908 creator A5076076101 @default.
• W4322774908 date "2023-03-01" @default.
• W4322774908 modified "2023-10-16" @default.
• W4322774908 title "Abstract P6-08-07: Reasons for Reduced Willingness to Participate in Clinical Trials During the COVID-19 Pandemic: The Translational Breast Cancer Research Consortium (TBCRC) 057 Survey" @default.
• W4322774908 doi "https://doi.org/10.1158/1538-7445.sabcs22-p6-08-07" @default.
• W4322774908 hasPublicationYear "2023" @default.
• W4322774908 type Work @default.
• W4322774908 citedByCount "0" @default.
• W4322774908 crossrefType "journal-article" @default.
• W4322774908 hasAuthorship W4322774908A5000761973 @default.
• W4322774908 hasAuthorship W4322774908A5022943610 @default.
• W4322774908 hasAuthorship W4322774908A5026024346 @default.
• W4322774908 hasAuthorship W4322774908A5026681970 @default.
• W4322774908 hasAuthorship W4322774908A5029658073 @default.
• W4322774908 hasAuthorship W4322774908A5032886944 @default.
• W4322774908 hasAuthorship W4322774908A5035746810 @default.
• W4322774908 hasAuthorship W4322774908A5048410090 @default.
• W4322774908 hasAuthorship W4322774908A5049065026 @default.
• W4322774908 hasAuthorship W4322774908A5052259481 @default.
• W4322774908 hasAuthorship W4322774908A5062171182 @default.
• W4322774908 hasAuthorship W4322774908A5064707298 @default.
• W4322774908 hasAuthorship W4322774908A5076076101 @default.
• W4322774908 hasConcept C118552586 @default.
• W4322774908 hasConcept C121608353 @default.
• W4322774908 hasConcept C126322002 @default.
• W4322774908 hasConcept C15744967 @default.
• W4322774908 hasConcept C180747234 @default.
• W4322774908 hasConcept C2779134260 @default.
• W4322774908 hasConcept C2779356329 @default.
• W4322774908 hasConcept C3008058167 @default.
• W4322774908 hasConcept C512399662 @default.
• W4322774908 hasConcept C524204448 @default.
• W4322774908 hasConcept C530470458 @default.
• W4322774908 hasConcept C535046627 @default.
• W4322774908 hasConcept C558461103 @default.
• W4322774908 hasConcept C71924100 @default.
• W4322774908 hasConcept C89623803 @default.
• W4322774908 hasConceptScore W4322774908C118552586 @default.
• W4322774908 hasConceptScore W4322774908C121608353 @default.
• W4322774908 hasConceptScore W4322774908C126322002 @default.
• W4322774908 hasConceptScore W4322774908C15744967 @default.
• W4322774908 hasConceptScore W4322774908C180747234 @default.
• W4322774908 hasConceptScore W4322774908C2779134260 @default.
• W4322774908 hasConceptScore W4322774908C2779356329 @default.
• W4322774908 hasConceptScore W4322774908C3008058167 @default.
• W4322774908 hasConceptScore W4322774908C512399662 @default.
• W4322774908 hasConceptScore W4322774908C524204448 @default.
• W4322774908 hasConceptScore W4322774908C530470458 @default.
• W4322774908 hasConceptScore W4322774908C535046627 @default.
• W4322774908 hasConceptScore W4322774908C558461103 @default.
• W4322774908 hasConceptScore W4322774908C71924100 @default.
• W4322774908 hasConceptScore W4322774908C89623803 @default.
• W4322774908 hasIssue "5_Supplement" @default.
• W4322774908 hasLocation W43227749081 @default.
• W4322774908 hasOpenAccess W4322774908 @default.
• W4322774908 hasPrimaryLocation W43227749081 @default.
• W4322774908 hasRelatedWork W3103289217 @default.
• W4322774908 hasRelatedWork W3106370311 @default.
• W4322774908 hasRelatedWork W3119540162 @default.
• W4322774908 hasRelatedWork W3121762836 @default.
• W4322774908 hasRelatedWork W3162081874 @default.
• W4322774908 hasRelatedWork W3194637846 @default.
• W4322774908 hasRelatedWork W4285097448 @default.
• W4322774908 hasRelatedWork W4312325145 @default.
• W4322774908 hasRelatedWork W4313474620 @default.
• W4322774908 hasRelatedWork W4327956415 @default.
• W4322774908 hasVolume "83" @default.
• W4322774908 isParatext "false" @default.
• W4322774908 isRetracted "false" @default.
• W4322774908 workType "article" @default.